Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors.

Sells TB, Chau R, Ecsedy JA, Gershman RE, Hoar K, Huck J, Janowick DA, Kadambi VJ, LeRoy PJ, Stirling M, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Balani SK, Bolen JB, Manfredi MG, Claiborne CF.

ACS Med Chem Lett. 2015 Apr 22;6(6):630-4. doi: 10.1021/ml500409n. eCollection 2015 Jun 11.

2.

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M.

Blood. 2014 Jan 30;123(5):632-9. doi: 10.1182/blood-2013-05-504340. Epub 2013 Dec 11.

3.

Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.

Milhollen MA, Thomas MP, Narayanan U, Traore T, Riceberg J, Amidon BS, Bence NF, Bolen JB, Brownell J, Dick LR, Loke HK, McDonald AA, Ma J, Manfredi MG, Sells TB, Sintchak MD, Yang X, Xu Q, Koenig EM, Gavin JM, Smith PG.

Cancer Cell. 2012 Mar 20;21(3):388-401. doi: 10.1016/j.ccr.2012.02.009.

4.

Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.

Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, Wysong DR, Janowick DA, Hyer ML, Leroy PJ, Gershman RE, Silva MD, Germanos MS, Bolen JB, Claiborne CF, Sells TB.

Clin Cancer Res. 2011 Dec 15;17(24):7614-24. doi: 10.1158/1078-0432.CCR-11-1536. Epub 2011 Oct 20.

5.

Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.

Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, Pickard M, Li Z, Tayber O, Li P, Hales P, Carsillo M, Neppalli VT, Berger AJ, Kupperman E, Manfredi M, Bolen JB, Van Ness B, Janz S.

Clin Cancer Res. 2011 Dec 1;17(23):7313-23. doi: 10.1158/1078-0432.CCR-11-0636. Epub 2011 Sep 8.

6.

Pillars article: the CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. 1994.

Veillette A, Bookman MA, Horak EM, Bolen JB.

J Immunol. 2010 Sep 1;185(5):2650-7. No abstract available.

7.

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.

Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E, Langston SP, Manfredi M, Narayanan U, Rolfe M, Staudt LM, Soucy TA, Yu J, Zhang J, Bolen JB, Smith PG.

Blood. 2010 Sep 2;116(9):1515-23. doi: 10.1182/blood-2010-03-272567. Epub 2010 Jun 4.

8.

Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.

Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, Soucy TA, Milhollen MA, Yang X, Burkhardt AL, Ma J, Loke HK, Lingaraj T, Wu D, Hamman KB, Spelman JJ, Cullis CA, Langston SP, Vyskocil S, Sells TB, Mallender WD, Visiers I, Li P, Claiborne CF, Rolfe M, Bolen JB, Dick LR.

Mol Cell. 2010 Jan 15;37(1):102-11. doi: 10.1016/j.molcel.2009.12.024.

9.

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, Cullis CA, Doucette A, Garnsey JJ, Gaulin JL, Gershman RE, Lublinsky AR, McDonald A, Mizutani H, Narayanan U, Olhava EJ, Peluso S, Rezaei M, Sintchak MD, Talreja T, Thomas MP, Traore T, Vyskocil S, Weatherhead GS, Yu J, Zhang J, Dick LR, Claiborne CF, Rolfe M, Bolen JB, Langston SP.

Nature. 2009 Apr 9;458(7239):732-6. doi: 10.1038/nature07884.

PMID:
19360080
10.

Assessment of the effects of tyrosine protein kinase inhibitors.

Burkhardt AL, Bolen JB.

Curr Protoc Immunol. 2001 May;Chapter 11:Unit 11.5. doi: 10.1002/0471142735.im1105s07.

PMID:
18432706
11.

Immune-complex assays for tyrosine protein kinases.

Burkhardt AL, Bolen JB.

Curr Protoc Immunol. 2001 May;Chapter 11:Unit 11.4. doi: 10.1002/0471142735.im1104s07.

PMID:
18432705
12.

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.

Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, Ray ET, Sells TB, Stringer B, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Bolen JB, Claiborne CF.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4106-11. Epub 2007 Feb 23.

13.

A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells.

Tomlinson MG, Woods DB, McMahon M, Wahl MI, Witte ON, Kurosaki T, Bolen JB, Johnston JA.

BMC Immunol. 2001;2:4. Epub 2001 Jun 8.

14.

The MMAC1 tumor suppressor phosphatase inhibits phospholipase C and integrin-linked kinase activity.

Morimoto AM, Tomlinson MG, Nakatani K, Bolen JB, Roth RA, Herbst R.

Oncogene. 2000 Jan 13;19(2):200-9.

15.

Identification and characterization of a myristylated and palmitylated serine/threonine protein kinase.

Berson AE, Young C, Morrison SL, Fujii GH, Sheung J, Wu B, Bolen JB, Burkhardt AL.

Biochem Biophys Res Commun. 1999 Jun 16;259(3):533-8.

PMID:
10364453
16.

Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1.

Maeda A, Scharenberg AM, Tsukada S, Bolen JB, Kinet JP, Kurosaki T.

Oncogene. 1999 Apr 8;18(14):2291-7.

17.

Reconstitution of Btk signaling by the atypical tec family tyrosine kinases Bmx and Txk.

Tomlinson MG, Kurosaki T, Berson AE, Fujii GH, Johnston JA, Bolen JB.

J Biol Chem. 1999 May 7;274(19):13577-85.

18.

Transcriptional analysis of the PTEN/MMAC1 pseudogene, psiPTEN.

Fujii GH, Morimoto AM, Berson AE, Bolen JB.

Oncogene. 1999 Mar 4;18(9):1765-9.

19.

Phenotypic analysis of human glioma cells expressing the MMAC1 tumor suppressor phosphatase.

Morimoto AM, Berson AE, Fujii GH, Teng DH, Tavtigian SV, Bookstein R, Steck PA, Bolen JB.

Oncogene. 1999 Feb 11;18(6):1261-6.

20.

Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer.

Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW, Wills KN, Shabram PW, Bolen JB, Tavtigian SV, Bookstein R.

Cancer Res. 1998 Jun 1;58(11):2331-4.

21.

Signaling pathways controlling trophoblast cell differentiation: Src family protein tyrosine kinases in the rat.

Kamei T, Hamlin GP, Chapman BM, Burkhardt AL, Bolen JB, Soares MJ.

Biol Reprod. 1997 Dec;57(6):1302-11.

PMID:
9408234
22.

Palmitylation of Src family tyrosine kinases regulates functional interaction with a B cell substrate.

Saouaf SJ, Wolven A, Resh MD, Bolen JB.

Biochem Biophys Res Commun. 1997 May 19;234(2):325-9.

PMID:
9177269
24.

Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines.

Hartmann F, Horak EM, Cho C, Lupu R, Bolen JB, Stetler-Stevenson MA, Pfreundschuh M, Waldmann TA, Horak ID.

Int J Cancer. 1997 Jan 17;70(2):221-9.

25.

Leukocyte protein tyrosine kinases: potential targets for drug discovery.

Bolen JB, Brugge JS.

Annu Rev Immunol. 1997;15:371-404. Review.

PMID:
9143693
26.

The Syk protein tyrosine kinase can function independently of CD45 or Lck in T cell antigen receptor signaling.

Chu DH, Spits H, Peyron JF, Rowley RB, Bolen JB, Weiss A.

EMBO J. 1996 Nov 15;15(22):6251-61.

27.

Specific association of tyrosine-phosphorylated c-Cbl with Fyn tyrosine kinase in T cells.

Tsygankov AY, Mahajan S, Fincke JE, Bolen JB.

J Biol Chem. 1996 Oct 25;271(43):27130-7.

28.

HIV infection--induced posttranslational modification of T cell signaling molecules associated with disease progression.

Stefanová I, Saville MW, Peters C, Cleghorn FR, Schwartz D, Venzon DJ, Weinhold KJ, Jack N, Bartholomew C, Blattner WA, Yarchoan R, Bolen JB, Horak ID.

J Clin Invest. 1996 Sep 15;98(6):1290-7.

29.

Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase.

Mallick-Wood CA, Pao W, Cheng AM, Lewis JM, Kulkarni S, Bolen JB, Rowley B, Tigelaar RE, Pawson T, Hayday AC.

Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9704-9.

30.

RANTES induces tyrosine kinase activity of stably complexed p125FAK and ZAP-70 in human T cells.

Bacon KB, Szabo MC, Yssel H, Bolen JB, Schall TJ.

J Exp Med. 1996 Sep 1;184(3):873-82.

31.

Role of hydroxyl radicals in radiation-induced activation of lyn tyrosine kinase in human B-cell precursors.

Xiao J, Biaglow JE, Chae-Park HJ, Jin J, Tuel-Ahlgren L, Myers DE, Burkhardt AL, Bolen JB, Uckun FM.

Leuk Lymphoma. 1996 Aug;22(5-6):421-30.

PMID:
8882955
32.

Expression of exogenous p59fyn modulates signaling in an immature B cell line, WEHI-231.

Iwabuchi N, Wu Y, Nguyen HP, Ido E, Kang J, Bolen JB, Burkhardt A, Hozumi N.

Immunol Lett. 1996 Jul;51(3):181-5.

PMID:
8832289
33.
35.

Physical and functional interactions between Lyn and p34cdc2 kinases in irradiated human B-cell precursors.

Uckun FM, Tuel-Ahlgren L, Waddick KG, Jun X, Jin J, Myers DE, Rowley RB, Burkhardt AL, Bolen JB.

J Biol Chem. 1996 Mar 15;271(11):6389-97.

36.

Endogenous reactive oxygen intermediates activate tyrosine kinases in human neutrophils.

Brumell JH, Burkhardt AL, Bolen JB, Grinstein S.

J Biol Chem. 1996 Jan 19;271(3):1455-61.

37.

Selective activation of T cell kinase p56lck by Herpesvirus saimiri protein tip.

Wiese N, Tsygankov AY, Klauenberg U, Bolen JB, Fleischer B, Bröker BM.

J Biol Chem. 1996 Jan 12;271(2):847-52.

38.

The SH3 domain of p56lck binds to proline-rich sequences in the cytoplasmic domain of CD2.

Bell GM, Fargnoli J, Bolen JB, Kish L, Imboden JB.

J Exp Med. 1996 Jan 1;183(1):169-78.

39.

Syk tyrosine kinase required for mouse viability and B-cell development.

Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T.

Nature. 1995 Nov 16;378(6554):303-6.

PMID:
7477353
40.

Reconstitution of the B cell antigen receptor signaling components in COS cells.

Saouaf SJ, Kut SA, Fargnoli J, Rowley RB, Bolen JB, Mahajan S.

J Biol Chem. 1995 Nov 10;270(45):27072-8.

41.

Syk mutation in Jurkat E6-derived clones results in lack of p72syk expression.

Fargnoli J, Burkhardt AL, Laverty M, Kut SA, van Oers NS, Weiss A, Bolen JB.

J Biol Chem. 1995 Nov 3;270(44):26533-7.

42.

Temporal activation of nontransmembrane protein-tyrosine kinases following mast cell Fc epsilon RI engagement.

Penhallow RC, Class K, Sonoda H, Bolen JB, Rowley RB.

J Biol Chem. 1995 Oct 6;270(40):23362-5.

43.

Structure and developmental regulation of the murine ctk gene.

Brinkley PM, Class K, Bolen JB, Penhallow RC.

Gene. 1995 Oct 3;163(2):179-84.

PMID:
7590263
44.

Src family protein tyrosine kinases induce autoactivation of Bruton's tyrosine kinase.

Mahajan S, Fargnoli J, Burkhardt AL, Kut SA, Saouaf SJ, Bolen JB.

Mol Cell Biol. 1995 Oct;15(10):5304-11.

45.
46.

Potentiation of B-cell antigen receptor-mediated signal transduction by the heterologous src family protein tyrosine kinase, src.

Lin J, Burkhardt AL, Bolen JB, Justement LB.

Ann N Y Acad Sci. 1995 Sep 7;766:214-5. No abstract available.

PMID:
7486661
47.

Nonreceptor protein tyrosine kinase involvement in signal transduction and immunodeficiency disease.

Saouaf SJ, Burkhardt AL, Bolen JB.

Clin Immunol Immunopathol. 1995 Sep;76(3 Pt 2):S151-7. Review.

PMID:
7554458
48.
49.

Protein tyrosine kinases in the initiation of antigen receptor signaling.

Bolen JB.

Curr Opin Immunol. 1995 Jun;7(3):306-11. Review.

PMID:
7546393
50.

Molecular cloning of rodent p72Syk. Evidence of alternative mRNA splicing.

Rowley RB, Bolen JB, Fargnoli J.

J Biol Chem. 1995 May 26;270(21):12659-64.

Supplemental Content

Loading ...
Support Center